TY - JOUR
T1 - Risk Factors and Outcomes of Recurrent Pregnancy Loss in Japan
AU - Morita, Keiko
AU - Ono, Yosuke
AU - Takeshita, Toshiyuki
AU - Sugi, Toshitaka
AU - Fujii, Tomoyuki
AU - Yamada, Hideto
AU - Nakatsuka, Mikiya
AU - Fukui, Atsushi
AU - Saito, Shigeru
N1 - Funding Information:
This study was supported by AMED under Grant Number JP18gk0110018h0003 and JSPS KAKENHI Grant Number JP15H04980.
Publisher Copyright:
© 2019 Japan Society of Obstetrics and Gynecology
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Aim: To clarify the risk factors and pregnancy outcomes for each risk factor of recurrent pregnancy loss (RPL) in Japan. Methods: Using a prospective RPL database collected from 16 facilities in Japan, the prevalence of risk factors for RPL, their treatments and pregnancy outcomes were examined. Results: Of 6663 patients registered in our database, 5708 patients had RPL. All examinations for risk factors were performed for 1340 patients (23.5%). The prevalences of positive antiphospholipid antibodies (aPL), malformation of the uterus, thyroid dysfunction, parental karyotype abnormality, factor XII deficiency, protein S deficiency and unknown risk factors were 8.7%, 7.9%, 9.5%, 3.7%, 7.6%, 4.3% and 65.1%, respectively. Although factor XII deficiency and protein S deficiency are not recognized as risk factors for RPL in general, low-dose aspirin (LDA) or unfractionated heparin + LDA therapy improved live birth rates. In transiently aPL-positive patients, the live birth rate with LDA therapy was similar to that with heparin + LDA. For unknown risk factors of RPL, the live birth rate in normal fetal karyotype in the none treatment group was similar to that in all other treatments group (81.3% vs 86.0%). Of 5708 RPL patients, pregnancy outcomes were known for 2261 patients and 1697 patients (75.1%) had at least one live birth. Conclusion: The risk factors and pregnancy outcomes for each risk factor of RPL are useful for clinicians and patients. Factor XII deficiency and protein S deficiency may be risk factors of RPL.
AB - Aim: To clarify the risk factors and pregnancy outcomes for each risk factor of recurrent pregnancy loss (RPL) in Japan. Methods: Using a prospective RPL database collected from 16 facilities in Japan, the prevalence of risk factors for RPL, their treatments and pregnancy outcomes were examined. Results: Of 6663 patients registered in our database, 5708 patients had RPL. All examinations for risk factors were performed for 1340 patients (23.5%). The prevalences of positive antiphospholipid antibodies (aPL), malformation of the uterus, thyroid dysfunction, parental karyotype abnormality, factor XII deficiency, protein S deficiency and unknown risk factors were 8.7%, 7.9%, 9.5%, 3.7%, 7.6%, 4.3% and 65.1%, respectively. Although factor XII deficiency and protein S deficiency are not recognized as risk factors for RPL in general, low-dose aspirin (LDA) or unfractionated heparin + LDA therapy improved live birth rates. In transiently aPL-positive patients, the live birth rate with LDA therapy was similar to that with heparin + LDA. For unknown risk factors of RPL, the live birth rate in normal fetal karyotype in the none treatment group was similar to that in all other treatments group (81.3% vs 86.0%). Of 5708 RPL patients, pregnancy outcomes were known for 2261 patients and 1697 patients (75.1%) had at least one live birth. Conclusion: The risk factors and pregnancy outcomes for each risk factor of RPL are useful for clinicians and patients. Factor XII deficiency and protein S deficiency may be risk factors of RPL.
KW - factor XII deficiency
KW - pregnancy outcomes
KW - protein S deficiency
KW - recurrent pregnancy loss
KW - risk factors
UR - http://www.scopus.com/inward/record.url?scp=85070297908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070297908&partnerID=8YFLogxK
U2 - 10.1111/jog.14083
DO - 10.1111/jog.14083
M3 - Article
C2 - 31397532
AN - SCOPUS:85070297908
SN - 1341-8076
VL - 45
SP - 1997
EP - 2006
JO - Journal of Obstetrics and Gynaecology Research
JF - Journal of Obstetrics and Gynaecology Research
IS - 10
ER -